Shots:
- ZipBio has entered into an exclusive license agreement with MeiraGTx, granting MeiraGTx exclusive right to AAV gene therapy to treat Geographic Atrophy
- Licensing deal will combine MeiraGTx’s expertise in vector design, clinical development, & in-house genetic medicine manufacturing with ZipBio’s de novo protein therapeutics created using its COMPACT generative AI platform
- As per the deal, ZipBio will receive an upfront payment, along with milestone & royalty payments; Although, financial terms were not disclosed
Ref: PRnewswire | Image: ZipBio & MeiraGTx | Press Release
Related News: Zonsen PepLib Biotech and Eli Lilly Partner to Advance Peptide-Based Therapies
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
